Core Viewpoint - Appili Therapeutics has received court approval for its transaction with Aditxt, allowing the acquisition of all issued and outstanding Class A common shares of the company, which was previously approved by shareholders [1][2]. Group 1: Transaction Details - The transaction with Aditxt is expected to close in Q4 2024, pending the satisfaction of certain closing conditions [2]. - Following the completion of the transaction, Appili's shares will be delisted from the Toronto Stock Exchange, and the company will cease to be a reporting issuer in Canada [3]. Group 2: Company Overview - Appili Therapeutics is focused on drug development for infectious diseases and medical countermeasures, aiming to address urgent infections with unmet needs [4]. - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate for biological threats, and a topical antiparasitic treatment [4].
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.